Phase II Randomised Trial of 5-azacitidine Versus 5-azacitidine in Combination With Vorinostat in Patients With Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy
Latest Information Update: 23 May 2022
At a glance
- Drugs Vorinostat (Primary) ; Azacitidine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms RAvVA
- 25 Jun 2017 Results assessing the molecular predictors of response to azacitidine therapy, presented at the 22nd Congress of the European Haematology Association
- 19 Jun 2017 According to a Celgene Corporation media release, data from this trial will be presented at the 22nd European Hematology Association annual meeting 2017.
- 06 Dec 2016 Primary endpoint (Phase II - Overall Survival) has not been met, according to the results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology